×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:BLCM

Bellicum Pharmaceuticals Stock Forecast, Price & News

$1.21
-0.01 (-0.82%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.20
$1.25
50-Day Range
$1.02
$2.00
52-Week Range
$1.00
$4.04
Volume
7,956 shs
Average Volume
42,355 shs
Market Capitalization
$10.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
30 days | 90 days | 365 days | Advanced Chart

Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Stock Forecast (MarketRank)

Overall MarketRank

1.86 out of 5 stars

Medical Sector

730th out of 1,418 stocks

Pharmaceutical Preparations Industry

354th out of 679 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
Bellicum Pharmaceuticals logo

About Bellicum Pharmaceuticals (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

BLCM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
7
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/24/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+313.2%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-9.70 million
Pretax Margin
-96.77%

Debt

Sales & Book Value

Annual Sales
$6.20 million
Book Value
$2.90 per share

Miscellaneous

Free Float
8,376,000
Market Cap
$10.42 million
Optionable
Optionable
Beta
1.46














Bellicum Pharmaceuticals Frequently Asked Questions

Should I buy or sell Bellicum Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Bellicum Pharmaceuticals stock.
View analyst ratings for Bellicum Pharmaceuticals
or view top-rated stocks.

What is Bellicum Pharmaceuticals' stock price forecast for 2022?

1 Wall Street analysts have issued 12-month price objectives for Bellicum Pharmaceuticals' shares. Their BLCM stock forecasts range from $5.00 to $5.00. On average, they predict Bellicum Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 313.2% from the stock's current price.
View analysts' price targets for Bellicum Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Bellicum Pharmaceuticals' stock performed in 2022?

Bellicum Pharmaceuticals' stock was trading at $1.49 on January 1st, 2022. Since then, BLCM shares have decreased by 18.8% and is now trading at $1.21.
View the best growth stocks for 2022 here
.

When is Bellicum Pharmaceuticals' next earnings date?

Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Bellicum Pharmaceuticals
.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter.
View Bellicum Pharmaceuticals' earnings history
.

When did Bellicum Pharmaceuticals' stock split? How did Bellicum Pharmaceuticals' stock split work?

Bellicum Pharmaceuticals's stock reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the following people:
  • Mr. Richard A. Fair, Pres, CEO & Director (Age 53, Pay $915.28k)
  • Ms. Charity D. Scripture M.S., Pharm.D., Chief Devel. Officer (Age 47, Pay $226.23k)
  • Mr. Charles S. Grass, Principal Accounting Officer (Age 62)
  • Mr. Joseph Senesac, Sr. VP of Technical Operations & Quality (Age 52)
  • Dr. Alan K. Smith Ph.D., Chief Scientific Officer (Age 64)
  • Dr. Aaron E. Foster, Head of Research & Sr. VP (Age 49)

What other stocks do shareholders of Bellicum Pharmaceuticals own?

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Who are Bellicum Pharmaceuticals' major shareholders?

Bellicum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.24%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Bellicum Pharmaceuticals stock include Richard A Fair and Shane Ward.
View institutional ownership trends for Bellicum Pharmaceuticals
.

Which major investors are selling Bellicum Pharmaceuticals stock?

BLCM stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc..
View insider buying and selling activity for Bellicum Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $1.21.

How much money does Bellicum Pharmaceuticals make?

Bellicum Pharmaceuticals (NASDAQ:BLCM) has a market capitalization of $10.42 million and generates $6.20 million in revenue each year. The biopharmaceutical company earns $-9.70 million in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Bellicum Pharmaceuticals have?

Bellicum Pharmaceuticals employs 7 workers across the globe.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The official website for Bellicum Pharmaceuticals is www.bellicum.com. The biopharmaceutical company can be reached via phone at (832) 384-1100 or via email at [email protected].

This page (NASDAQ:BLCM) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.